Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.

Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

HighField has received clearance for its IND application from the CDE of China's NMPA to commence the Phase I trial of HF50.

As of 2005, 83% of babies with critical congenital heart defects were expected to live past one year, up from 67% in 1993.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Precision has gained the approval of its CTA in Hong Kong to study PBGENE-HBV in the Phase I trial for curing chronic hepatitis B.

A new report identifies that China has had the largest number of Parkinson's disease trials in APAC since 2019.

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early Parkinson's disease (PD).